<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Dopaminergics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i554.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i554.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i554.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i553.htm" title="Previous: Domperidone">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i1066.htm" title="Next: Rotigotine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i554">Dopaminergics</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Dopaminergics</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i942.htm">Memantine</a></td><td>effects of  dopaminergics possibly enhanced by memantine </td><td></td></tr><tr><td><a href="41001i611.htm">Methyldopa</a></td><td>antiparkinsonian effect of  dopaminergics antagonised by methyldopa </td><td></td></tr></tbody></table><p><b>Rotigotine</b> belongs to
      <b>Dopaminergics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i363.htm">Antipsychotics</a></td><td>manufacturer of  rotigotine advises avoid concomitant use of antipsychotics (antagonism of effect)</td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i613.htm">Metoclopramide</a></td><td>manufacturer of  rotigotine advises avoid concomitant use of metoclopramide (antagonism of effect)</td><td></td></tr></tbody></table><p><b>Rasagiline</b> belongs to
      <b>Dopaminergics</b>
          and has the following interaction information:
        </p><div>Rasagiline is a MAO-B inhibitor</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>










<tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td class="cBV"><b>increased risk of CNS toxicity when  rasagiline given with SSRIs </b></td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>increased risk of CNS toxicity when  rasagiline given with tricyclics </b></td><td></td></tr><tr><td><a href="41001i195.htm">Ciprofloxacin</a></td><td>plasma concentration of  rasagiline increased by ciprofloxacin </td><td></td></tr><tr><td><a href="41001i882.htm">Dextromethorphan</a></td><td class="cBV"><b>avoid concomitant use of  rasagiline with dextromethorphan </b></td><td></td></tr><tr><td><a href="41001i854.htm">Entacapone</a></td><td>plasma concentration of  rasagiline possibly reduced by entacapone </td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td class="cBV"><b>after stopping  rasagiline do not start fluoxetine for 2 weeks, also rasagiline should not be started until at least 5 weeks after stopping fluoxetine</b></td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td class="cBV"><b>after stopping  rasagiline do not start fluvoxamine for 2 weeks</b></td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>risk of hypertensive crisis when  rasagiline given with MAOIs , avoid MAOIs for at least 2 weeks after stopping rasagiline</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i102.htm">Pethidine</a></td><td class="cBV"><b>risk of CNS toxicity when  rasagiline given with pethidine (avoid pethidine for 2 weeks after rasagiline)</b></td><td></td></tr><tr><td><a href="41001i690.htm">Sympathomimetics</a></td><td class="cBV"><b>avoid concomitant use of  rasagiline with sympathomimetics </b></td><td></td></tr></tbody></table><p><b>Tolcapone</b> belongs to
      <b>Dopaminergics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i257.htm">MAOIs</a></td><td>avoid concomitant use of  tolcapone with MAOIs </td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr></tbody></table><p><b>Apomorphine</b> belongs to
      <b>Dopaminergics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i363.htm">Antipsychotics</a></td><td>effects of  apomorphine antagonised by antipsychotics </td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i854.htm">Entacapone</a></td><td>effects of  apomorphine possibly enhanced by entacapone </td><td></td></tr></tbody></table><p><b>Selegiline</b> belongs to
      <b>Dopaminergics</b>
          and has the following interaction information:
        </p><div>Selegiline is a MAO-B inhibitor</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




















<tr><td><a href="41001i572.htm">5HT<sub>1</sub>-receptor Agonists</a></td><td>manufacturer of  selegiline advises avoid concomitant use with 5HT<sub>1</sub> agonists </td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td class="cBV"><b>CNS toxicity reported when  selegiline given with tricyclics </b></td><td></td></tr><tr><td><a href="41001i233.htm">Citalopram</a></td><td>manufacturer of  selegiline advises avoid concomitant use with citalopram </td><td></td></tr><tr><td><a href="41001i703.htm">Dopamine</a></td><td class="cBV"><b>risk of hypertensive crisis when  selegiline given with dopamine </b></td><td></td></tr><tr><td><a href="41001i854.htm">Entacapone</a></td><td>max. dose of 10mg  selegiline advised by manufacturer of entacapone if used concomitantly</td><td></td></tr><tr><td><a href="41001i964.htm">Escitalopram</a></td><td>manufacturer of  selegiline advises avoid concomitant use with escitalopram </td><td></td></tr><tr><td><a href="41001i234.htm">Fluoxetine</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  selegiline given with fluoxetine (selegiline should not be started until 5 weeks after stopping fluoxetine, avoid fluoxetine for 2 weeks after stopping selegiline)</b></td><td></td></tr><tr><td><a href="41001i235.htm">Fluvoxamine</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  selegiline given with fluvoxamine (selegiline should not be started until 1 week after stopping fluvoxamine, avoid fluvoxamine for 2 weeks after stopping selegiline)</b></td><td></td></tr><tr><td><a href="41001i558.htm">Levodopa</a></td><td> selegiline enhances effects and increases toxicity of levodopa (reduce dose of levodopa)</td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>enhanced hypotensive effect when  selegiline given with MAOIs—manufacturer of selegiline advises avoid concomitant use</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i942.htm">Memantine</a></td><td>effects of  selegiline possibly enhanced by memantine </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>avoid concomitant use of  selegiline with moclobemide </b></td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td class="cBV"><b>plasma concentration of  selegiline increased by oestrogens—manufacturer of selegiline advises avoid concomitant use</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i85.htm">Opioid Analgesics</a></td><td>manufacturer of  selegiline advises avoid concomitant use with opioid analgesics </td><td></td></tr><tr><td><a href="41001i236.htm">Paroxetine</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  selegiline given with paroxetine (selegiline should not be started until 2 weeks after stopping paroxetine, avoid paroxetine for 2 weeks after stopping selegiline)</b></td><td></td></tr><tr><td><a href="41001i102.htm">Pethidine</a></td><td class="cBV"><b>hyperpyrexia and CNS toxicity reported when  selegiline given with pethidine (avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i664.htm">Progestogens</a></td><td class="cBV"><b>plasma concentration of  selegiline increased by progestogens—manufacturer of selegiline advises avoid concomitant use</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i237.htm">Sertraline</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  selegiline given with sertraline (selegiline should not be started until 1 week after stopping sertraline, avoid sertraline for 2 weeks after stopping selegiline)</b></td><td></td></tr><tr><td><a href="41001i690.htm">Sympathomimetics</a></td><td>manufacturer of  selegiline advises avoid concomitant use with sympathomimetics </td><td></td></tr><tr><td><a href="41001i240.htm">Venlafaxine</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  selegiline given with venlafaxine (selegiline should not be started until 1 week after stopping venlafaxine, avoid venlafaxine for 2 weeks after stopping selegiline)</b></td><td></td></tr></tbody></table><p><b>Pergolide</b> belongs to
      <b>Dopaminergics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i363.htm">Antipsychotics</a></td><td>effects of  pergolide antagonised by antipsychotics </td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i613.htm">Metoclopramide</a></td><td>antiparkinsonian effect of  pergolide antagonised by metoclopramide </td><td></td></tr></tbody></table><p><b>Amantadine</b> belongs to
      <b>Dopaminergics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






<tr><td><a href="41001i363.htm">Antipsychotics</a></td><td>increased risk of extrapyramidal side-effects when  amantadine given with antipsychotics </td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i896.htm">Bupropion</a></td><td>increased risk of side-effects when  amantadine given with bupropion </td><td></td></tr><tr><td><a href="41001i942.htm">Memantine</a></td><td class="cBV"><b>increased risk of CNS toxicity when  amantadine given with memantine (manufacturer of memantine advises avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i611.htm">Methyldopa</a></td><td>increased risk of extrapyramidal side-effects when  amantadine given with methyldopa </td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td>plasma concentration of  amantadine possibly increased by quinine </td><td></td></tr><tr><td><a href="41001i733.htm">Tetrabenazine</a></td><td>increased risk of extrapyramidal side-effects when  amantadine given with tetrabenazine </td><td></td></tr></tbody></table><p><b>Bromocriptine</b> belongs to
      <b>Dopaminergics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>








<tr><td><a href="41001i20.htm">Alcohol</a></td><td>tolerance of  bromocriptine reduced by alcohol </td><td></td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td>hypoprolactinaemic and antiparkinsonian effects of  bromocriptine antagonised by antipsychotics </td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i553.htm">Domperidone</a></td><td>hypoprolactinaemic effect of  bromocriptine possibly antagonised by domperidone </td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td>plasma concentration of  bromocriptine increased by erythromycin (increased risk of toxicity)</td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i717.htm">Isometheptene</a></td><td class="cBV"><b>risk of toxicity when  bromocriptine given with isometheptene </b></td><td></td></tr><tr><td><a href="41001i166.htm">Macrolides</a></td><td>plasma concentration of  bromocriptine possibly increased by macrolides (increased risk of toxicity)</td><td><i>See also</i> Telithromycin</td></tr><tr><td><a href="41001i613.htm">Metoclopramide</a></td><td>hypoprolactinaemic effect of  bromocriptine antagonised by metoclopramide </td><td></td></tr><tr><td><a href="41001i584.htm">Octreotide</a></td><td>plasma concentration of  bromocriptine increased by octreotide </td><td></td></tr></tbody></table><p><b>Cabergoline</b> belongs to
      <b>Dopaminergics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





<tr><td><a href="41001i363.htm">Antipsychotics</a></td><td>hypoprolactinaemic and antiparkinsonian effects of  cabergoline antagonised by antipsychotics </td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i553.htm">Domperidone</a></td><td>hypoprolactinaemic effect of  cabergoline possibly antagonised by domperidone </td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td>plasma concentration of  cabergoline increased by erythromycin (increased risk of toxicity)</td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i166.htm">Macrolides</a></td><td>plasma concentration of  cabergoline possibly increased by macrolides (increased risk of toxicity)</td><td><i>See also</i> Telithromycin</td></tr><tr><td><a href="41001i613.htm">Metoclopramide</a></td><td>hypoprolactinaemic effect of  cabergoline antagonised by metoclopramide </td><td></td></tr></tbody></table><p><b>Entacapone</b> belongs to
      <b>Dopaminergics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>














<tr><td><a href="41001i715.htm">Adrenaline (epinephrine)</a></td><td> entacapone possibly enhances effects of adrenaline (epinephrine) </td><td></td></tr><tr><td><a href="41001i241.htm">Antidepressants, Tricyclic</a></td><td>manufacturer of  entacapone advises caution with tricyclics </td><td></td></tr><tr><td><a href="41001i430.htm">Apomorphine</a></td><td> entacapone possibly enhances effects of apomorphine </td><td></td></tr><tr><td><a href="41001i702.htm">Dobutamine</a></td><td> entacapone possibly enhances effects of dobutamine </td><td></td></tr><tr><td><a href="41001i703.htm">Dopamine</a></td><td> entacapone possibly enhances effects of dopamine </td><td></td></tr><tr><td><a href="41001i587.htm">Iron</a></td><td>absorption of  entacapone reduced by <i>oral</i> iron </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>avoid concomitant use of  entacapone with non-selective MAOIs </b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i611.htm">Methyldopa</a></td><td> entacapone possibly enhances effects of methyldopa </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td>manufacturer of  entacapone advises caution with moclobemide </td><td></td></tr><tr><td><a href="41001i711.htm">Noradrenaline (norepinephrine)</a></td><td> entacapone possibly enhances effects of noradrenaline (norepinephrine) </td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td> entacapone possibly reduces plasma concentration of rasagiline </td><td>Rasagiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td>manufacturer of   entacapone advises max. dose of 10mg selegiline if used concomitantly</td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i240.htm">Venlafaxine</a></td><td>manufacturer of  entacapone advises caution with venlafaxine </td><td></td></tr><tr><td><a href="41001i222.htm">Warfarin</a></td><td class="cBV"><b> entacapone enhances anticoagulant effect of warfarin </b></td><td></td></tr></tbody></table><p><b>Levodopa</b> belongs to
      <b>Dopaminergics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>





























<tr><td><a href="41001i2.htm">ACE Inhibitors</a></td><td>enhanced hypotensive effect when  levodopa given with ACE inhibitors </td><td></td></tr><tr><td><a href="41001i15.htm">Adrenergic Neurone Blockers</a></td><td>enhanced hypotensive effect when  levodopa given with adrenergic neurone blockers </td><td></td></tr><tr><td><a href="41001i26.htm">Alpha-blockers</a></td><td>enhanced hypotensive effect when  levodopa given with alpha-blockers </td><td></td></tr><tr><td><a href="41001i809.htm">Amisulpride</a></td><td>avoidance of  levodopa advised by manufacturer of amisulpride (antagonism of effect)</td><td></td></tr><tr><td><a href="41001i46.htm">Anaesthetics, General (volatile liquids)</a></td><td class="cBV"><b>increased risk of arrhythmias when  levodopa given with volatile liquid general anaesthetics </b></td><td></td></tr><tr><td><a href="41001i107.htm">Angiotensin-II Receptor Antagonists</a></td><td>enhanced hypotensive effect when  levodopa given with angiotensin-II receptor antagonists </td><td></td></tr><tr><td><a href="41001i342.htm">Antimuscarinics</a></td><td>absorption of  levodopa possibly reduced by antimuscarinics </td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td>effects of  levodopa antagonised by antipsychotics </td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i617.htm">Baclofen</a></td><td>possible agitation, confusion and hallucinations when  levodopa given with baclofen </td><td></td></tr><tr><td><a href="41001i405.htm">Benzodiazepines</a></td><td>effects of  levodopa possibly antagonised by benzodiazepines </td><td></td></tr><tr><td><a href="41001i440.htm">Beta-blockers</a></td><td>enhanced hypotensive effect when  levodopa given with beta-blockers </td><td>Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</td></tr><tr><td><a href="41001i896.htm">Bupropion</a></td><td>increased risk of side-effects when  levodopa given with bupropion </td><td></td></tr><tr><td><a href="41001i466.htm">Calcium-channel Blockers</a></td><td>enhanced hypotensive effect when  levodopa given with calcium-channel blockers </td><td>Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</td></tr><tr><td><a href="41001i482.htm">Clonidine</a></td><td>enhanced hypotensive effect when  levodopa given with clonidine </td><td></td></tr><tr><td><a href="41001i522.htm">Diazoxide</a></td><td>enhanced hypotensive effect when  levodopa given with diazoxide </td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td>enhanced hypotensive effect when  levodopa given with diuretics </td><td></td></tr><tr><td><a href="41001i763.htm">Hydralazine</a></td><td>enhanced hypotensive effect when  levodopa given with hydralazine </td><td></td></tr><tr><td><a href="41001i587.htm">Iron</a></td><td>absorption of  levodopa possibly reduced by <i>oral</i> iron </td><td></td></tr><tr><td><a href="41001i165.htm">Isoniazid</a></td><td>effects of  levodopa possibly reduced by isoniazid </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>risk of hypertensive crisis when  levodopa given with MAOIs , avoid levodopa for at least 2 weeks after stopping MAOIs</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i611.htm">Methyldopa</a></td><td>enhanced hypotensive effect when  levodopa given with methyldopa </td><td></td></tr><tr><td><a href="41001i764.htm">Minoxidil</a></td><td>enhanced hypotensive effect when  levodopa given with minoxidil </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td>increased risk of side-effects when  levodopa given with moclobemide </td><td></td></tr><tr><td><a href="41001i615.htm">Moxonidine</a></td><td>enhanced hypotensive effect when  levodopa given with moxonidine </td><td></td></tr><tr><td><a href="41001i631.htm">Nitrates</a></td><td>enhanced hypotensive effect when  levodopa given with nitrates </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td>effects of  levodopa possibly reduced by phenytoin </td><td></td></tr><tr><td><a href="41001i804.htm">Pyridoxine</a></td><td>effects of  levodopa reduced by pyridoxine when given without dopa-decarboxylase inhibitor</td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td>enhanced effects and increased toxicity of  levodopa when given with  selegiline (reduce dose of levodopa)</td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i765.htm">Sodium Nitroprusside</a></td><td>enhanced hypotensive effect when  levodopa given with sodium nitroprusside </td><td></td></tr></tbody></table><p><b>Co-careldopa</b> belongs to
      <b>Dopaminergics</b>
          but has no specific interaction information.
        </p><p><b>Co-beneldopa</b> belongs to
      <b>Dopaminergics</b>
          but has no specific interaction information.
        </p><p><b>Pramipexole</b> belongs to
      <b>Dopaminergics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i363.htm">Antipsychotics</a></td><td>manufacturer of  pramipexole advises avoid concomitant use of antipsychotics (antagonism of effect)</td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>excretion of  pramipexole reduced by cimetidine (increased plasma concentration)</td><td></td></tr></tbody></table><p><b>Quinagolide</b> belongs to
      <b>Dopaminergics</b>
          but has no specific interaction information.
        </p><p><b>Ropinirole</b> belongs to
      <b>Dopaminergics</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>




<tr><td><a href="41001i363.htm">Antipsychotics</a></td><td>manufacturer of  ropinirole advises avoid concomitant use of antipsychotics (antagonism of effect)</td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i195.htm">Ciprofloxacin</a></td><td>metabolism of  ropinirole inhibited by ciprofloxacin (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i613.htm">Metoclopramide</a></td><td>manufacturer of  ropinirole advises avoid concomitant use of metoclopramide (antagonism of effect)</td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td>plasma concentration of  ropinirole increased by oestrogens </td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i1066.htm" title="Rotigotine">Rotigotine</a></li><li><a href="41001i1051.htm" title="Rasagiline">Rasagiline</a></li><li><a href="41001i1042.htm" title="Tolcapone">Tolcapone</a></li><li><a href="41001i430.htm" title="Apomorphine">Apomorphine</a></li><li><a href="41001i687.htm" title="Selegiline">Selegiline</a></li><li><a href="41001i659.htm" title="Pergolide">Pergolide</a></li><li><a href="41001i555.htm" title="Amantadine">Amantadine</a></li><li><a href="41001i556.htm" title="Bromocriptine">Bromocriptine</a></li><li><a href="41001i557.htm" title="Cabergoline">Cabergoline</a></li><li><a href="41001i854.htm" title="Entacapone">Entacapone</a></li><li id="_41001i558"><a href="41001i558.htm" title="Levodopa">Levodopa</a></li><li><a href="41001i881.htm" title="Pramipexole">Pramipexole</a></li><li><a href="41001i560.htm" title="Quinagolide">Quinagolide</a></li><li><a href="41001i686.htm" title="Ropinirole">Ropinirole</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i553.htm">Previous: Domperidone</a> | <a class="top" href="41001i554.htm#">Top</a> | <a accesskey="]" href="41001i1066.htm">Next: Rotigotine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>